Company: IMRX
Filing Date: 2025-08-13
Form Type: S-3
Source: 0001104659-25-077655
Chunk: 52

Company: Immuneering Corp
Filing Date: 2025-08-13
Form: S-3
Chunk 52
---
 |
| ​ | Dilution per share to new investors participating in the offering                 | ​ | ​ | ​ | ​ |    ​ | ​ | ​ | ​ | ​ | $ | 1.48 | ​ | ​ |

The above discussion and table are based on 35,987,306 shares of our Class A common stock outstanding as of June 30, 2025, and excludes: • 8,405,371 shares of Class A common stock issuable upon exercise of stock options outstanding under our equity incentive plans as of June 30, 2025, at a weighted average exercise price of $3.78 per share; • 937,983 shares of Class A common stock reserved for future issuance under our 2021 Incentive Award Plan; • 1,051,390 shares of Class A common stock reserved for future issuance under our 2021 Employee Stock Purchase Plan; and • 382,000 shares of Class A common stock reserved for future issuance under our 2025 Employment Inducement Award Plan. The foregoing table does not give effect to the exercise of any outstanding options. We may raise additional capital in the future through the sale of equity or convertible debt securities. To the extent options are exercised, or we issue shares of Class A common stock in connection with raising additional capital, there may be further dilution to new investors.

S-12

TABLE OF CONTENTS

### PLAN OF DISTRIBUTION
We have entered into the Equity Distribution Agreement with Piper Sandler, under which we may offer and sell Class A common stock having an aggregate offering price of up to $100,000,000 from time to time through Piper Sandler acting as agent. Sales of our shares of Class A common stock, if any, under this prospectus supplement and the accompanying prospectus will be made by any method that is deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act.

Each time we wish to issue and sell our shares of Class A common stock under the Equity Distribution Agreement, we will notify Piper Sandler of the number of shares to be issued, the time period during which such sales are requested to be made, any limitation on the number of shares to be sold in any one day and any minimum price below which sales may not be made. Once we have so instructed Piper Sandler, unless Piper Sandler declines to accept the terms of such notice, Piper Sandler has agreed to use its commercially reasonable efforts consistent with its normal